26 February 2014
SAREUM HOLDINGS PLC
(“Sareum” or “the Company”)
HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2013
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce its half-yearly results for the six month period ended 31 December 2013.
Financial highlights
Operational highlights
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: “The Company has made good progress having now secured co-development agreements for three of its lead programmes that will provide additional resources and expertise. As a result of the recent oversubscribed Placing and the existing SEDA financing facility we are well positioned to advance our existing programmes and collaborations, and build our pipeline of new drugs.”
The full report is avaialble as a pdf document: Financial Results for the Six Months Ended 31/12/2013
Sareum Holdings plc |
|
Tim Mitchell, Chief Executive Officer |
01223 497 700 |
Sanlam Securities UK Limited (Nominated Adviser) |
|
Simon Clements |
020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce / William Lynne |
020 7947 4350 / 4361 |
The Communications Portfolio (Media enquiries) |
|
Ariane Comstive |
020 7536 2028
|